Trial record 1 of 1 for:    CLBH589BUS48T
Previous Study | Return to List | Next Study

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) (BUS48T)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by Georgia Regents University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Anand Jillella, Georgia Health Sciences University
ClinicalTrials.gov Identifier:
NCT01504776
First received: August 8, 2011
Last updated: January 4, 2012
Last verified: January 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: April 2014
  Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)